SCHEDULE: Pontifax Funds Disclose 7.7% Stake in Climb Bio

Investment funds managed by Pontifax have reported a 7.7% beneficial ownership stake in Climb Bio, Inc. common stock.

Summary

• Pontifax VI G.P. L.P., Pontifax Management 4 G.P. (2015) Ltd., Ran Nussbaum, and Tomer Kariv collectively reported beneficial ownership of 5,206,380 shares of Climb Bio, Inc. common stock.
• This ownership represents 7.7% of the total class of securities for Climb Bio, Inc.
• The shares are held through Pontifax (Israel) VI L.P. (3,312,625 shares) and Pontifax (Cayman) VI L.P. (1,893,755 shares).
• The reporting persons, including Mr. Kariv and Mr. Nussbaum, disclaim beneficial ownership of the shares held by the Pontifax entities, stating that the inclusion in this Schedule 13G is not an admission of beneficial ownership.
• The reporting persons have shared voting power and shared dispositive power over all 5,206,380 shares.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment score. It simply reports a significant stake by an institutional investor.

Positives

• A significant institutional investor, Pontifax, has disclosed a substantial stake in Climb Bio, Inc., potentially indicating confidence in the company's future prospects.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Climb Bio, Inc., which is common in the biotechnology and life sciences sectors where venture capital and specialized funds often take substantial early-stage or growth-stage equity positions. The disclosure of a 7.7% stake by Pontifax, an Israeli-based life sciences investor, suggests continued investor interest in companies within this industry.

Stakeholder Impact

• Shareholders are informed of a new significant institutional holder, which could influence market perception and trading activity.
• The company's management gains insight into a major investor's position, potentially affecting future investor relations and strategic decisions.

Key Dates

Keywords

Climb Bio, Pontifax, Schedule 13G, beneficial ownership, institutional investor, common stock, equity stake